S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:NPCE

NeuroPace (NPCE) Stock Price, News & Analysis

$13.98
-0.02 (-0.14%)
(As of 04/19/2024 ET)
Today's Range
$13.49
$14.30
50-Day Range
$12.37
$17.50
52-Week Range
$3.80
$18.15
Volume
96,236 shs
Average Volume
129,772 shs
Market Capitalization
$367.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

NeuroPace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
12.1% Upside
$15.67 Price Target
Short Interest
Healthy
0.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of NeuroPace in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$6.97 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.14) to ($1.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

466th out of 909 stocks

Surgical & Medical Instruments Industry

53rd out of 96 stocks

NPCE stock logo

About NeuroPace Stock (NASDAQ:NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Stock Price History

NPCE Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
NeuroPace (NASDAQ: NPCE)
The Latest Analyst Ratings For NeuroPace
Recap: NeuroPace Q4 Earnings
NeuroPace GAAP EPS of -$0.23
See More Headlines
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/20/2024
Next Earnings (Confirmed)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
171
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.67
High Stock Price Target
$22.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+12.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-32,960,000.00
Pretax Margin
-50.38%

Debt

Sales & Book Value

Annual Sales
$65.42 million
Book Value
$0.79 per share

Miscellaneous

Free Float
19,056,000
Market Cap
$367.39 million
Optionable
Optionable
Beta
2.08
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Martha J. Morrell (Age 67)
    Chief Medical Officer
    Comp: $555.87k
  • Mr. Joel D. Becker (Age 56)
    CEO, President & Director
  • Ms. Rebecca L. Kuhn (Age 63)
    CFO, VP of Finance & Administration and Assistant Secretary
    Comp: $440.92k
  • Ms. Kelley Nicholas
    Vice President of Sales
  • Ms. Irene Thomas (Age 55)
    Vice President of Human Resources

NPCE Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings
or view top-rated stocks.

What is NeuroPace's stock price target for 2024?

7 Wall Street research analysts have issued 12-month price targets for NeuroPace's stock. Their NPCE share price targets range from $9.00 to $22.00. On average, they expect the company's share price to reach $15.67 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts price targets for NPCE
or view top-rated stocks among Wall Street analysts.

How have NPCE shares performed in 2024?

NeuroPace's stock was trading at $10.31 on January 1st, 2024. Since then, NPCE shares have increased by 35.6% and is now trading at $13.98.
View the best growth stocks for 2024 here
.

Are investors shorting NeuroPace?

NeuroPace saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,900 shares, an increase of 178.0% from the March 15th total of 30,900 shares. Based on an average trading volume of 98,900 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.7% of the shares of the stock are sold short.
View NeuroPace's Short Interest
.

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NPCE earnings forecast
.

How can I listen to NeuroPace's earnings call?

NeuroPace will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.10. The business had revenue of $18.01 million for the quarter, compared to the consensus estimate of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative trailing twelve-month return on equity of 153.76%.

What guidance has NeuroPace issued on next quarter's earnings?

NeuroPace issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $73.0 million-$77.0 million, compared to the consensus revenue estimate of $74.6 million.

When did NeuroPace IPO?

NeuroPace (NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NPCE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners